MYELODYSPLASTIC SYNDROMES
Clinical trials for MYELODYSPLASTIC SYNDROMES explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROMES trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROMES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental drug gentulizumab tested for tough blood cancers – but trial halted early
Disease control TerminatedThis early-stage trial tested a new drug called gentulizumab in 58 people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had come back or stopped responding to treatment. Gentulizumab is an antibody that helps the immune system attack cancer cells. The m…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental INKmune therapy for blood cancers halted after just 2 patients
Disease control TerminatedThis early-stage study tested an experimental drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find a safe dose and check for side effects. However, the study was stopped early after only 2 people enrolled, so no c…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental combo for MDS and AML shows early promise but trial halted
Disease control TerminatedThis early-phase trial tested an experimental drug called SL-172154, given alongside standard chemotherapy drugs, for people with higher-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goals were to check safety and find the right dose. The study was…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Experimental MDS drug trial halted early – what we know
Disease control TerminatedThis study tested a drug called MBG453 in 10 people with a type of bone marrow disorder called lower-risk myelodysplastic syndromes (MDS). The goal was to see if the drug could improve blood cell counts and reduce the need for transfusions. The trial was terminated early, so the …
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New cell therapy aims to stop transplant complications in blood cancer patients
Disease control TerminatedThis early-phase study tested whether a special type of cell (interferon gamma-primed mesenchymal stromal cells) could be safely given to prevent graft-versus-host disease, a common and serious complication after bone marrow transplant. Only 4 patients with acute leukemia or myel…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Edwin Horwitz • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental combo for rare blood cancers hits roadblock
Disease control TerminatedThis study tested whether adding sabatolimab to standard chemotherapy (azacitidine) helps people with high-risk myelodysplastic syndrome (MDS) or a related leukemia (CMML-2). The trial aimed to see if the combination improved survival. However, the study was stopped early, so we …
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for MDS patients? study tests MBG453 combo but ends early
Disease control TerminatedThis study tested adding an experimental drug called MBG453 to standard chemotherapy for people with a serious bone marrow disorder called myelodysplastic syndrome (MDS). The trial included 127 adults with high-risk MDS who could not have a stem cell transplant. The goal was to s…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental blood cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called SAR443579 in adults and children with certain blood cancers that had come back or not responded to treatment. The goal was to see if the drug was safe and could shrink or control the cancer. The trial was stopped early, so results are limited.
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New pill combo aims to fight tough bone marrow cancer
Disease control TerminatedThis study tested two oral drugs, eltanexor and Inqovi, in adults with high-risk myelodysplastic syndromes (MDS) that did not improve with standard treatment. MDS is a bone marrow disorder that can lead to leukemia. The goal was to find a safe dose and see if the combination help…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental combo for tough blood cancers hits early hurdle
Disease control TerminatedThis early-stage trial tested a new drug called DSP107 combined with standard chemotherapy drugs (azacitidine and venetoclax) in 25 people with relapsed or hard-to-treat acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia. The study aimed to check…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Kahr Medical • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug trial halted early: what we know
Disease control TerminatedThis study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New anemia drug for MDS and myeloma patients shows early promise but trial halted
Disease control TerminatedThis study tested a daily pill called INCB000928 for people with anemia caused by myelodysplastic syndromes (MDS) or multiple myeloma. The goal was to see if it was safe and could raise red blood cell levels, reducing the need for transfusions. The trial was terminated early afte…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New antibody cocktail aimed at MDS shows early promise, but study halted
Disease control TerminatedThis early-phase study tested combinations of three antibody drugs (sabatolimab, NIS793, and canakinumab) in 33 adults with lower-risk myelodysplastic syndrome (MDS), a blood disorder. The main goal was to check safety and find the right doses. The study was terminated early, so …
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental MDS drug trial halted after just 2 patients
Disease control TerminatedThis early-phase trial tested a new drug called BMS-986253, alone or with standard chemotherapy, for people with myelodysplastic syndromes (MDS), a group of bone marrow disorders. The study aimed to find a safe dose and see if the drug could shrink cancer. However, the trial was …
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Immune cell therapy shows promise for tough leukemia cases
Disease control TerminatedThis study tested a treatment called TCB008, made from donated immune cells, for adults with acute myeloid leukemia (AML) that came back or didn't respond to standard therapy. The goal was to see if it could reduce cancer cells in the bone marrow. The trial was stopped early, but…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE2 • Sponsor: TC Biopharm • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental leukemia drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called CC-95251, alone or with other cancer drugs, in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that had come back or not responded to treatment. The main goals were to check safety and find the right dose…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Tiny study hopes to predict blood cancer risk from genetic mutations
Knowledge-focused TerminatedThis study aimed to find genetic mutations in people with idiopathic cytopenia of undetermined significance (ICUS), a condition of unexplained low blood cell counts. Researchers wanted to see if these mutations are similar to those found in myelodysplastic syndrome (MDS), a type …
Matched conditions: MYELODYSPLASTIC SYNDROMES
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Leukemia drug pill tested against IV version – but study halted early
Knowledge-focused TerminatedThis very early study aimed to compare an oral (pill) version of the chemotherapy drug cladribine with the standard IV (vein) version in people with certain leukemias. Only 3 people took part before the study was stopped early. The main goal was to see how the body handles the or…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC